
Xenon Pharmaceuticals fell 3.3% from $40.61 to $39.26, behind the S&P 500's +10.0%. Its worst day was Sep 18 (−30.7%), and its low came Oct 16 at $33.49.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.31 missed the $-1.20 estimate on $0.00 revenue.
−3.8% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
Xenon Pharmaceuticals shares rose 49.6%, while the S&P 500 rose 0.9%.
+49.6%, the year's best day · S&P 500 +0.9%
EPS of $-1.17 beat the $-1.19 estimate on $0.00 revenue (est. $3.8M).
+0.8% · S&P 500 +0.8%
Xenon Pharmaceuticals closed at its highest level of the year, 74.7% above where the year started.
+1.4% · S&P 500 +0.8%
EPS of $-1.11 beat the $-1.16 estimate on $0.00 revenue (est. $937,500.00).
−1.8% · S&P 500 +0.6%
New Drug Application for azetukalner in focal seizures submitted to U.S.
−30.7%, the year's worst day, on 18M shares, the year's heaviest volume · S&P 500 +0.1%
Xenon Pharmaceuticals closed at its lowest level of the year, 17.5% below where the year started.
−2.4% · S&P 500 −1.1%
EPS of $-1.11 beat the $-1.15 estimate on $0.00 revenue.
+2.3% · S&P 500 −0.4%
Where it ended: a close of $39.26 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-1.20, revenue est. $846,000.00).
Nothing in the past 12 months.
All XENE dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for XENE and SPY from Benzinga historical bars. Not investment advice.